Cargando…

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Kevin J, Leon-Ferre, Roberto A, Sinnwell, Jason P, Zahrieh, David M, Suman, Vera J, Metzger, Filho Otto, Asad, Sarah, Stover, Daniel G, Carey, Lisa, Sikov, William M, Ingle, James N, Liu, Minetta C, Carter, Jodi M, Klee, Eric W, Weinshilboum, Richard M, Boughey, Judy C, Wang, Liewei, Couch, Fergus J, Goetz, Matthew P, Kalari, Krishna R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Cancer Computational Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204893/ https://www.ncbi.nlm.nih.gov/pubmed/35734391 http://dx.doi.org/10.1093/narcan/zcac018

Ejemplares similares

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
por: Kohale, Ishwar N., et al.
Publicado: (2022)

Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
por: Tang, Xiaojia, et al.
Publicado: (2023)

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall
por: Moyer, Ann M., et al.
Publicado: (2019)

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
por: Wei, Lixuan, et al.
Publicado: (2023)

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
por: Carter, Jodi M., et al.
Publicado: (2023)

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
por: Cairns, Junmei, et al.
Publicado: (2019)

Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
por: Norton, Nadine, et al.
Publicado: (2020)

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
por: Park, Jae-Hyun, et al.
Publicado: (2016)

Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX)
por: Zhuang, Yongxian, et al.
Publicado: (2021)

Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study
por: Wang, Liewei, et al.
Publicado: (2017)

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2017)

Regulation of sister chromatid cohesion by nuclear PD-L1
por: Yu, Jia, et al.
Publicado: (2020)

Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1
por: Yu, Jia, et al.
Publicado: (2020)

A comprehensive analysis of breast cancer microbiota and host gene expression
por: Thompson, Kevin J., et al.
Publicado: (2017)

PDJ amplicon in triple negative breast cancer
por: Roesler, Alexander S., et al.
Publicado: (2023)

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer
por: Zhuang, Yongxian, et al.
Publicado: (2019)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2022)

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy
por: Ellingson, Marissa S., et al.
Publicado: (2015)

SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
por: Zhang, Lingxin, et al.
Publicado: (2021)

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
por: Yu, Jia, et al.
Publicado: (2017)

Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
por: Yu, Jia, et al.
Publicado: (2021)

ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion
por: Qin, Sisi, et al.
Publicado: (2021)

Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach
por: Kalari, Krishna R, et al.
Publicado: (2010)

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
por: Jalalirad, Mohammad, et al.
Publicado: (2021)

HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data
por: Baheti, Saurabh, et al.
Publicado: (2018)

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
por: Liu, Duan, et al.
Publicado: (2017)

SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1
por: Cairns, Junmei, et al.
Publicado: (2017)

Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
por: Aspros, Kirsten G. M., et al.
Publicado: (2022)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
por: Zhang, Lingxin, et al.
Publicado: (2020)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks
por: Kohale, Ishwar N., et al.
Publicado: (2021)

Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion
por: Qin, Sisi, et al.
Publicado: (2017)

Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer
por: Behrens, Marshall D., et al.
Publicado: (2022)

Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer
por: Athreya, Arjun P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gotqkntm6s696bo58lg1srgauf